Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD - read this article along with other careers information, tips and advice on BioSpace
Opthea Appoints Julia A. Haller, MD, and Judith Robertson globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Opthea Appoints Company Secretary and Vice President of Finance streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Company, with effect 24 June 2021. Opthea has initiated a search for a permanent replacement with requisite expertise in financial reporting and company secretarial duties for a dual ASX and Nasdaq listed company. Mr Tonroe leaves Opthea at a time of corporate growth and emerging presence in the US to align with the recent listing on Nasdaq and initiation of the Company’s global Phase 3 clinical development program for OPT-302 in wet age-related macular degeneration (wet AMD).